Check out the companies making the biggest moves in noon deals after a rival spirit airline bankruptcy filed on Friday. Humana – After reassessing its 2025 earnings forecast on Friday, the health insurance company’s shares rose more than 2%. Humana expects to make around $17 per share, adjusted. Following the announcement, Bank of America raised its price target but reiterated its neutral stance towards Equity United therapies. Biotechnology has surged 35% after saying it evaluated the use of major pulmonary papillary inhalation solutions to evaluate the use of neblysed Tyvaso (treprostinil) inhalation solutions to treat major pulmonary myofibrosis, which treats idiopathic pulmonary myofibrosis. Ionis Pharmaceuticals – RNA-targeted drug manufacturer jumped 32% when stating the Phase 3 Core and Core2 study of Orezalsen in patients with severe hypertriglyceridemia. PepsiCo – After activist investor Elliott Management took $4 billion in stake in the company, the snack and drink giant rose more than 2%, touting the “unusual” and “historic” opportunity to turn around with the iconic soft drink and snack company. The investment by Elliott, founded by Paul Singer, was first reported by the Wall Street Journal. Currently one of Pepsi’s five largest active investors, Elliott sent a presentation and letter to Pepsi’s board on Tuesday to detail the agenda to regain business momentum. Kraft Heinz – The stock fell nearly 7% after the food company confirmed with previous reports that its previous reports were split into two publicly traded companies. One unit currently being run by Global Taste Elevation includes Kraft shelves stable products such as Heinz and Kraft Mac & Cheese. The other is “North American grocery” includes brands such as Oscar Mayer and Lantable. Constellation Brands – Shares fell 7% after brewers cut their year-round guidance. Currently, revenue is expected to be between $10.77 and $11.07 per share, down from previous guidance at $12.07 and $12.37 per share. Air Leases – Shares rose more than 6% after the aircraft leasing company reached a merger agreement with Apollo, Brookfield, SMBC Air Capital and Sumitomo. The contract is expected to close in the first half of next year, valueating the company at around $28.2 billion, including debt. Cytokinetics – Late-stage biopharmaceutical companies rose 40% in a clinical trial of Aficamten, a cardiac drug clinical trial, after showing meaningful improvements over the standard of care, metoprolol, in patients with symptomatic obstructive hypertrophic cardiomyopathy. LAM Research – Inventory fell 4% after the downgrade at Morgan Stanley. The bank said it does not expect LAM research to sustain growth in 2026. Biogen – Biopharma Stock added nearly 4% after Biogen and Eisai, and the Food and Drug Administration said it has approved Leqembi, an injectable version of the Alzheimer’s drug. NEWMONT – Gold miners scored 2% early in Tuesday’s session after precious metals hit a record high of $3,508.50. —CNBC’s Scott Schnipper, Michelle Fox, Fred Inbert and Alex Hurling reported.
